Omeprazol Hikma (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Hikma, is a proton pump inhibitor presented as a 20 mg tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazol Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazol Hikma is a proton pump inhibitor that acts on the gastric acid secretion pathway to manage several acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Peptic ulcer disease: supports ulcer healing by maintaining a low‑acid environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens (as adjunct): enhances the effectiveness of antibiotic therapy by reducing gastric acidity. - NSA‑induced gastropathy prophylaxis: lowers risk of ulcer formation in patients requiring long‑term NSAID therapy.

Adverse reactions to omeprazole are generally mild and dose‑dependent, but serious events can occur.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhea: loose stools occurring in a minority of patients. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort or cramping. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis linked to altered gut flora. - Vitamin B12 deficiency: long‑term use may impair absorption. - Hypomagnesemia: low serum magnesium with prolonged therapy. - Acute interstitial nephritis: rare kidney inflammation. - Stevens‑Johnson syndrome: severe skin reaction, extremely uncommon. - Fracture risk: possible increase in hip, wrist or spine fractures with long‑term use.

When prescribing Omeprazol Hikma, clinicians should consider several safety aspects.

- Assess renal and hepatic function: adjust use in severe impairment. - Review long‑term therapy need: limit duration when possible to reduce risk of nutrient deficiencies. - Monitor for infection signs: be alert to Clostridioides difficile symptoms. - Evaluate concomitant medications: consider potential for altered drug absorption. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir and other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Digoxin: higher serum levels possible, observe for toxicity. - Methotrexate (high dose): reduced clearance, watch for toxicity. - Phenytoin: decreased plasma concentrations, may require dose adjustment.